Biomarkers of Fast Acting Therapies in Major Depression

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

August 31, 2019

Study Completion Date

August 31, 2019

Conditions
Major Depressive Disorder
Interventions
DRUG

Ketamine

Approved FDA indications for ketamine include use as an adjunct in the induction and maintenance of general anesthesia and for procedural sedation. For general anesthesia, ketamine is given at dosages ranging from 1-2mg/kg and given either as bolus injection or run continuously (0.1 to 0.3mg/kg/min) in conjunction with another anesthetic or sedation agent. In this study, ketamine at a subanesthetic dose of 0.5mg/kg will be diluted in 60cc of normal saline and administered via a slow IV infusion over 40 minutes at each treatment session in patients while undergoing hemodynamic monitoring. When used in this manner, ketamine infusion does not induce general anesthesia or states of unconsciousness, and patients remain fully awake, responsive to commands, and do not lose respiratory drive.

Trial Locations (1)

90095

Geffen School of Medicine, UCLA, Los Angeles

All Listed Sponsors
collaborator

National Institute of Mental Health (NIMH)

NIH

lead

University of California, Los Angeles

OTHER

NCT02165449 - Biomarkers of Fast Acting Therapies in Major Depression | Biotech Hunter | Biotech Hunter